Head and Neck Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...
NK cells with bispecific antibody yield high response rates in patients with lymphoma: Clinical trial
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...
Healio52m
‘Pivotal moment’: Uplizna becomes first FDA-approved treatment for IgG4-related disease
The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...